Arcturus to prioritize mRNA therapeutics in bid to boost rare disease programs
Arcturus Therapeutics is doubling down on mRNA technology.
The biotech said Monday that it’s prioritizing its experimental mRNA drugs, with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
